HR+/HER2- Breast Cancer Market 2027 by Treatment, End-User | The Insight Partners

HR+/HER2- Breast Cancer Market Forecast to 2027 - Covid-19 Impact and Global Analysis By Treatment ( Chemotherapy, Surgery and Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy ); End-User ( Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others )

Report Code: TIPRE00016406 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

HR-positive breast cancer treatments about 74 percent of all breast cancers are both HR-positive and HER2-negative. Breast cancer that starts in the luminal cells that line the mammary ducts is called luminal breast cancer.

MARKET DYNAMICS

The HR+/HER2- breast cancer market is driving due to expected launch of breast cancer emerging therapies along with rising cases of breast cancer. Moreover, various awareness programs conducted by organizations will further offer lucrative opportunities in the market in the review period. However, high cost of the treatment, adverse effects associated with the therapy and long approval time for the drugs might hamper the market growth.

MARKET SCOPE

The "HR+/HER2- Breast Cancer Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of HR+/HER2- breast cancer market with detailed market segmentation by treatment and end-user. The HR+/HER2- breast cancer market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in HR+/HER2- breast cancer market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The HR+/HER2- breast cancer market is segmented on the basis of treatment and end-user. On the basis of treatment, the market is segmented into chemotherapy, surgery and radiation therapy, targeted therapy, biologic therapy, hormone therapy. On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the HR+/HER2- Breast Cancer market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The HR+/HER2- Breast Cancer market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting HR+/HER2- Breast Cancer market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the HR+/HER2- Breast Cancer market in these regions.



Get more information on this report :

MARKET PLAYERS

The report covers key developments in the HR+/HER2- breast cancer market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from HR+/HER2- breast cancer market are anticipated to have lucrative growth opportunities in the future with the rising demand for HR+/HER2- breast cancer market in the global market. Below mentioned is the list of few companies engaged in the HR+/HER2- breast cancer market.

The report also includes the profiles of key players in HR+/HER2- breast cancer market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Jiangsu HengRui Medicine Co.
- Odonate Therapeutics
- Radius Pharmaceuticals
- Immunomedics
- Roche Group
- Syndax Pharmaceuticals
- Merck Sharp & Dohme Corp
- Eagle Pharmaceuticals
- Merrimack Pharmaceuticals
- GlaxoSmithKline

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.



Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 HR+/HER2- Breast Cancer Market - By Treatment
1.3.2 HR+/HER2- Breast Cancer Market - By End-User
1.3.3 HR+/HER2- Breast Cancer Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HR+/HER2- BREAST CANCER MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HR+/HER2- BREAST CANCER MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HR+/HER2- BREAST CANCER MARKET - GLOBAL MARKET ANALYSIS
6.1. HR+/HER2- BREAST CANCER - GLOBAL MARKET OVERVIEW
6.2. HR+/HER2- BREAST CANCER - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. HR+/HER2- BREAST CANCER MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT
7.1. OVERVIEW
7.2. TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. SURGERY AND RADIATION THERAPY
7.4.1. Overview
7.4.2. Surgery and Radiation Therapy Market Forecast and Analysis
7.5. TARGETED THERAPY
7.5.1. Overview
7.5.2. Targeted Therapy Market Forecast and Analysis
7.6. BIOLOGIC THERAPY
7.6.1. Overview
7.6.2. Biologic Therapy Market Forecast and Analysis
7.7. HORMONE THERAPY
7.7.1. Overview
7.7.2. Hormone Therapy Market Forecast and Analysis
8. HR+/HER2- BREAST CANCER MARKET - REVENUE AND FORECASTS TO 2027 - END-USER
8.1. OVERVIEW
8.2. END-USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. CLINICS
8.4.1. Overview
8.4.2. Clinics Market Forecast and Analysis
8.5. AMBULATORY SURGICAL CENTERS
8.5.1. Overview
8.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
8.6. DIAGNOSTIC CENTERS
8.6.1. Overview
8.6.2. Diagnostic Centers Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. HR+/HER2- BREAST CANCER MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America HR+/HER2- Breast Cancer Market Overview
9.1.2 North America HR+/HER2- Breast Cancer Market Forecasts and Analysis
9.1.3 North America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Treatment
9.1.4 North America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By End-User
9.1.5 North America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Countries
9.1.5.1 United States HR+/HER2- Breast Cancer Market
9.1.5.1.1 United States HR+/HER2- Breast Cancer Market by Treatment
9.1.5.1.2 United States HR+/HER2- Breast Cancer Market by End-User
9.1.5.2 Canada HR+/HER2- Breast Cancer Market
9.1.5.2.1 Canada HR+/HER2- Breast Cancer Market by Treatment
9.1.5.2.2 Canada HR+/HER2- Breast Cancer Market by End-User
9.1.5.3 Mexico HR+/HER2- Breast Cancer Market
9.1.5.3.1 Mexico HR+/HER2- Breast Cancer Market by Treatment
9.1.5.3.2 Mexico HR+/HER2- Breast Cancer Market by End-User
9.2. EUROPE
9.2.1 Europe HR+/HER2- Breast Cancer Market Overview
9.2.2 Europe HR+/HER2- Breast Cancer Market Forecasts and Analysis
9.2.3 Europe HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Treatment
9.2.4 Europe HR+/HER2- Breast Cancer Market Forecasts and Analysis - By End-User
9.2.5 Europe HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Countries
9.2.5.1 Germany HR+/HER2- Breast Cancer Market
9.2.5.1.1 Germany HR+/HER2- Breast Cancer Market by Treatment
9.2.5.1.2 Germany HR+/HER2- Breast Cancer Market by End-User
9.2.5.2 France HR+/HER2- Breast Cancer Market
9.2.5.2.1 France HR+/HER2- Breast Cancer Market by Treatment
9.2.5.2.2 France HR+/HER2- Breast Cancer Market by End-User
9.2.5.3 Italy HR+/HER2- Breast Cancer Market
9.2.5.3.1 Italy HR+/HER2- Breast Cancer Market by Treatment
9.2.5.3.2 Italy HR+/HER2- Breast Cancer Market by End-User
9.2.5.4 Spain HR+/HER2- Breast Cancer Market
9.2.5.4.1 Spain HR+/HER2- Breast Cancer Market by Treatment
9.2.5.4.2 Spain HR+/HER2- Breast Cancer Market by End-User
9.2.5.5 United Kingdom HR+/HER2- Breast Cancer Market
9.2.5.5.1 United Kingdom HR+/HER2- Breast Cancer Market by Treatment
9.2.5.5.2 United Kingdom HR+/HER2- Breast Cancer Market by End-User
9.2.5.6 Rest of Europe HR+/HER2- Breast Cancer Market
9.2.5.6.1 Rest of Europe HR+/HER2- Breast Cancer Market by Treatment
9.2.5.6.2 Rest of Europe HR+/HER2- Breast Cancer Market by End-User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific HR+/HER2- Breast Cancer Market Overview
9.3.2 Asia-Pacific HR+/HER2- Breast Cancer Market Forecasts and Analysis
9.3.3 Asia-Pacific HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Treatment
9.3.4 Asia-Pacific HR+/HER2- Breast Cancer Market Forecasts and Analysis - By End-User
9.3.5 Asia-Pacific HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Countries
9.3.5.1 Australia HR+/HER2- Breast Cancer Market
9.3.5.1.1 Australia HR+/HER2- Breast Cancer Market by Treatment
9.3.5.1.2 Australia HR+/HER2- Breast Cancer Market by End-User
9.3.5.2 China HR+/HER2- Breast Cancer Market
9.3.5.2.1 China HR+/HER2- Breast Cancer Market by Treatment
9.3.5.2.2 China HR+/HER2- Breast Cancer Market by End-User
9.3.5.3 India HR+/HER2- Breast Cancer Market
9.3.5.3.1 India HR+/HER2- Breast Cancer Market by Treatment
9.3.5.3.2 India HR+/HER2- Breast Cancer Market by End-User
9.3.5.4 Japan HR+/HER2- Breast Cancer Market
9.3.5.4.1 Japan HR+/HER2- Breast Cancer Market by Treatment
9.3.5.4.2 Japan HR+/HER2- Breast Cancer Market by End-User
9.3.5.5 South Korea HR+/HER2- Breast Cancer Market
9.3.5.5.1 South Korea HR+/HER2- Breast Cancer Market by Treatment
9.3.5.5.2 South Korea HR+/HER2- Breast Cancer Market by End-User
9.3.5.6 Rest of Asia-Pacific HR+/HER2- Breast Cancer Market
9.3.5.6.1 Rest of Asia-Pacific HR+/HER2- Breast Cancer Market by Treatment
9.3.5.6.2 Rest of Asia-Pacific HR+/HER2- Breast Cancer Market by End-User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa HR+/HER2- Breast Cancer Market Overview
9.4.2 Middle East and Africa HR+/HER2- Breast Cancer Market Forecasts and Analysis
9.4.3 Middle East and Africa HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Treatment
9.4.4 Middle East and Africa HR+/HER2- Breast Cancer Market Forecasts and Analysis - By End-User
9.4.5 Middle East and Africa HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa HR+/HER2- Breast Cancer Market
9.4.5.1.1 South Africa HR+/HER2- Breast Cancer Market by Treatment
9.4.5.1.2 South Africa HR+/HER2- Breast Cancer Market by End-User
9.4.5.2 Saudi Arabia HR+/HER2- Breast Cancer Market
9.4.5.2.1 Saudi Arabia HR+/HER2- Breast Cancer Market by Treatment
9.4.5.2.2 Saudi Arabia HR+/HER2- Breast Cancer Market by End-User
9.4.5.3 U.A.E HR+/HER2- Breast Cancer Market
9.4.5.3.1 U.A.E HR+/HER2- Breast Cancer Market by Treatment
9.4.5.3.2 U.A.E HR+/HER2- Breast Cancer Market by End-User
9.4.5.4 Rest of Middle East and Africa HR+/HER2- Breast Cancer Market
9.4.5.4.1 Rest of Middle East and Africa HR+/HER2- Breast Cancer Market by Treatment
9.4.5.4.2 Rest of Middle East and Africa HR+/HER2- Breast Cancer Market by End-User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America HR+/HER2- Breast Cancer Market Overview
9.5.2 South and Central America HR+/HER2- Breast Cancer Market Forecasts and Analysis
9.5.3 South and Central America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Treatment
9.5.4 South and Central America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By End-User
9.5.5 South and Central America HR+/HER2- Breast Cancer Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil HR+/HER2- Breast Cancer Market
9.5.5.1.1 Brazil HR+/HER2- Breast Cancer Market by Treatment
9.5.5.1.2 Brazil HR+/HER2- Breast Cancer Market by End-User
9.5.5.2 Argentina HR+/HER2- Breast Cancer Market
9.5.5.2.1 Argentina HR+/HER2- Breast Cancer Market by Treatment
9.5.5.2.2 Argentina HR+/HER2- Breast Cancer Market by End-User
9.5.5.3 Rest of South and Central America HR+/HER2- Breast Cancer Market
9.5.5.3.1 Rest of South and Central America HR+/HER2- Breast Cancer Market by Treatment
9.5.5.3.2 Rest of South and Central America HR+/HER2- Breast Cancer Market by End-User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL HR+/HER2- BREAST CANCER MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. HR+/HER2- BREAST CANCER MARKET, KEY COMPANY PROFILES
12.1. JIANGSU HENGRUI MEDICINE CO.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ODONATE THERAPEUTICS
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. RADIUS PHARMACEUTICALS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. IMMUNOMEDICS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ROCHE GROUP
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SYNDAX PHARMACEUTICALS
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. MERCK SHARP AND DOHME CORP
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. EAGLE PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERRIMACK PHARMACEUTICALS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. GLAXOSMITHKLINE
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Jiangsu HengRui Medicine Co.
2. Odonate Therapeutics
3. Radius Pharmaceuticals
4. Immunomedics
5. Roche Group
6. Syndax Pharmaceuticals
7. Merck Sharp & Dohme Corp
8. Eagle Pharmaceuticals
9. Merrimack Pharmaceuticals
10. GlaxoSmithKline

TIPRE00016406
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking